Why Is Nano-Cap Allarity Therapeutics Stock Trading Up On Thursday?
Why Is Nano-Cap Allarity Therapeutics Stock Trading Up On Thursday?
Allarity Therapeutics Inc (NASDAQ:ALLR) shares are trading higher on a strong session volume of 67 million, as per the data from Benzinga Pro.
根據Benzinga Pro的數據，Allarity Therapeutics Inc（納斯達克股票代碼：ALLR）股價上漲，交易量強勁，爲6700萬個。
The company announced the early discontinuation of its Phase 2 clinical trial of stenoparib for advanced recurrent ovarian cancer.
該公司宣佈提前停止針對晚期複發性卵巢癌的stenoparib的2期臨床試驗。
The patients enrolled in the trial had been pre-screened by Allarity's Drug Response predictor (DRP) companion diagnostic to treat only patients with the highest likelihood of deriving clinical benefit.
參加該試驗的患者已通過Alarity的藥物反應預測因子（DRP）伴隨診斷進行預篩選，僅治療獲得臨床獲益可能性最高的患者。
The trial, evaluating stenoparib given twice daily, has shown clear clinical benefits, including tumor shrinkage and long-term disease stability, in heavily pretreated ovarian cancer patients.
該試驗評估了每天給藥兩次的stenoparib，已顯示出明顯的臨床益處，包括腫瘤縮小和長期疾病穩定性，對預先治療的卵巢癌患者有明顯的臨床益處。
These results have provided sufficient clinical proof of concept for stenoparib as monotherapy, prompting Allarity to halt further enrollment in this trial to enable and accelerate the development of a follow-on trial with FDA regulatory intent.
這些結果爲Stenoparib作爲單一療法的概念提供了足夠的臨床證明，促使Alarity停止了該試驗的進一步註冊，以支持和加快具有FDA監管意圖的後續試驗的開發。
"Based on the substantial clinical benefit observed in the early stages of the trial, we have achieved proof of concept results that surpassed our initial expectations and provided the critical insights we were seeking," stated Thomas Jensen, CEO of Allarity Therapeutics.
Allarity Therapeutics首席執行官托馬斯·詹森表示：“基於在試驗早期觀察到的實質性臨床益處，我們取得了超出我們最初預期的概念驗證結果，並提供了我們正在尋求的關鍵見解。”
"Concluding the trial now is the most effective way to re-allocate our financial resources to develop a follow-on trial with the fastest route to regulatory submission for stenoparib."
“現在結束試驗是重新分配我們的財政資源以開發後續試驗的最有效方法，以最快的速度向監管機構提交stenoparib的申請。”
This company's decision will not affect the ongoing treatment of current patients, as described in greater detail in Allarity's March 27, 2024, press release.
正如Alarity在2024年3月27日的新聞稿中詳細描述的那樣，該公司的決定不會影響當前患者的持續治療。
ALLR Price Action: Allarity Therapeutics shares are up 6.57% at $1.46 at the last check Thursday.
ALLR價格走勢：在週四的最後一次檢查中，Allarity Therapeutics股價上漲6.57％，至1.46美元。
Photo: Louis Reed via Unsplash
照片：路易斯·裏德通過 Unsplash
譯文內容由第三人軟體翻譯。